Composition and Use of Alternatively Formatted Anti-Mesothelin Antibodies for the Treatment of Cancer
AssigneeNavrogen, Inc.
InventorsLuigi Grasso, Nicholas C. Nicolaides, James Bradford Kline
Life of this patent
Estimating the term…
Loading patent…
AssigneeNavrogen, Inc.
InventorsLuigi Grasso, Nicholas C. Nicolaides, James Bradford Kline
Estimating the term…
Tumors utilize multiple mechanisms to avoid the host's anti-tumor immune response. Humoral immunosuppression is one of the mechanisms. Tumors produce circulating factors that can suppress antibody or complement-mediated immune responses to enhance their own survival. Mesothelin is a cell surface protein overexpressed by several cancer types that are associated with tumors exhibiting immunosuppressed microenvironments. Anti-mesothelin antibodies are often subject to such immunosuppressive microenvironments. Alternatively formatted anti-mesothelin antibodies, however, are effective in killing mesothelin-expressing cancers irrespective of tumor microenvironment immune status.
An antibody-drug conjugate (ADC) comprising an anti-mesothelin antibody comprising complementary determining regions (CDRs) with amino acids as shown in SEQ ID NOs:
A method of treating a cancer patient who has a mesothelin-expressing tumor, comprising:
A bispecific antibody (BSP) comprising a mesothelin-binding portion comprising amino acid sequences SEQ ID NOs:
Dependencies are inferred from the claim text.